Innovative Therapeutics ARTHEx Biotech specializes in developing first-in-class oligonucleotide therapies targeting microRNA, creating opportunities to collaborate with pharmaceutical companies seeking novel treatments for unmet medical needs, particularly rare diseases like Myotonic Dystrophy Type 1.

Recent Funding Momentum With an $87 million Series B financing round led by Bpifrance, ARTHEx demonstrates strong investor confidence and growth potential, making it an attractive partner for biotech investors and strategic alliances focused on RNA and gene modulation therapies.

Focused Disease Targets ARTHEx's focus on rare, high-need diseases such as DM1 presents an opportunity to connect with biotech and pharma companies interested in expanding their portfolio into genetic and microRNA-based personalized medicine.

European Market Presence Based in Valencia, Spain, ARTHEx offers an entry point for organizations looking to establish or expand collaborations within the European biomedical ecosystem, especially in the innovative gene therapy sector with a strong academic and research background.

Early-Stage Growth As a clinical-stage biotech with ongoing development programs and a growing financial runway, ARTHEx is positioned for potential licensing deals, technology partnerships, and clinical trial collaborations to accelerate pipeline advancement.